The Blood and Marrow Transplant Program at Northside Hospital (NH-BMT) provides the best of both worlds—clinical excellence and compassionate care. We are committed to being the premier program in the Southeast, providing exceptional, state-of-the-art care to patients undergoing acute leukemia treatment, CAR T-cell immunotherapy, and blood and marrow stem cell transplantation. New patient brochure
2024 National Leaders in Allogeneic Transplantation
NH-BMT is the ONLY BMT program in the country and the only BMT program in Georgia to have achieved survival outcomes that significantly exceeded the expected survival rate for allogeneic and unrelated donor transplants for the last 16 consecutive reporting cycles (2009–2024) and is one of only 12 national centers (less than 10% of all centers) to over-perform for the current annual reporting cycle.
The Program’s actual one-year survival rate, as reported in the December 2024 Center for International Blood and Marrow Transplant Research (CIBMTR) final 2024 Transplant Center Specific Survival Report and nmdp.org is 82.6%.*
For additional survival data details, visit bmtga.com/bmt-survival-data.
*Survival information includes only patients who received their first allogeneic transplant between January 1, 2020 and December 31, 2022, using unrelated or related donors and who had reported follow-up.
Dr. Hong De Sa Joins the Blood and Marrow Transplant Group of Georgia and the Northside BMT/Leukemia/Immunotherapy Programs
We are delighted to welcome Dr. Hong De Sa to our practice and programs. Dr. De Sa is board certified in Internal Medicine and Pediatrics, with fellowship training in adult and pediatric hematology and oncology.
She has authored or co-authored multiple research articles and abstracts in leading peer-reviewed journals, including the Journal of Pediatric Hematology Oncology, Research and Practice in Thrombosis and Haemostasis, Leukemia & Lymphoma, Cancer Research, and the Journal of Clinical Oncology.
Dr. De Sa’s clinical and research interests include blood and marrow transplantation, CAR T-cell therapy, TIL therapy, and acute leukemia and hematologic malignancy therapies.
We are proud to have Dr. De Sa join our team and look forward to the expertise, passion, and innovation she brings to our patients, colleagues, and the broader medical community.
Dr. De Sa can be reached at 404-255-1930.
Northside brings breakthrough Melanoma treatment to Atlanta
Northside Hospital is leading the way to bringing advanced cancer immunotherapies, like Tumor Infiltrating Lymphocyte (TIL) therapy, to Georgia. FOX LOCAL host Alyse Eady talks to Dr. Liza Bachier about the breakthrough Melanoma treatment.
Bill’s story: Advanced cancer care offered hope close to home
When Bill Clark of Avondale Estates, then 65 years old, thinks back to the spring of 2020, he remembers a life that felt full and steady. He was in excellent health, leading a thriving architectural and engineering firm and enjoying time with family and friends in Atlanta. Then, just as the world was adjusting to the challenges of COVID-19, Bill’s life changed dramatically. What started as concerning inflammation near his left eye quickly led to a diagnosis that would define the next five years — conjunctival melanoma, a rare and aggressive cancer.
Bill recalled, “The diagnosis was shocking. I knew melanoma was serious. I had friends who had it and didn’t survive it.”
Even as the wider health care system faced new and unforeseen challenges due to the pandemic, Bill was able to undergo surgery to remove his left eye. He recovered well and adapted to his new normal with resilience and, for a time, no further treatment was recommended. Life resumed its regular pace.
Amtagvi (lifileucel) is now available as SECOND line therapy for patients with unresectable or metastatic melanoma
Northside’s Immunotherapy Program is the FIRST approved TIL treatment center in Georgia.
Eligibility: To schedule a patient consultation, please call The Blood & Marrow Transplant Group of Georgia at 404-255-1930.
>18 years of age with unresectable or metastatic melanoma
Must have progressed on at least 1 previous systemic therapy, including a PD-L1 antibody, and if they had BRAF V600E mutation-positive disease, a BRAF or BRAF/MEK inhibitor
At least 1 resectable lesion
Patient Stories
From pain to hope: A sickle cell survivor's journey
Chelsea Uche, a 23-year-old sickle cell survivor, shares her inspiring journey from diagnosis to overcoming the challenges of living with this inherited blood disorder. Diagnosed with sickle cell shortly after birth, Chelsea describes how the disease affected her physically, emotionally and socially.
“Growing up with sickle cell, I had a very tough time with everything, truthfully. I was in the hospital consistently. I suffered with very bad chronic pain,” she said. Click Here to read full interview
Natalie’s story: From diagnosis to double transplant
After battling uterine fibroids, Natalie Grubbs was unexpectedly diagnosed with acute lymphoblastic leukemia, followed by a rare secondary cancer that required two stem cell transplants. Here, the Atlanta resident shares her story in her own words — from diagnosis and treatment to healing, hope and resilience. What are the events that led up to your cancer diagnosis?
Before my cancer diagnosis, I had suffered from uterine fibroids for years. The fibroids caused miscarriages, a distended abdomen and excruciating periods with extremely heavy.......Click Here to read full interview
Momta's story: Surviving leukemia and heart failure
In 1993, while living in New York City, Momta Jahan was diagnosed with and treated for acute myeloid leukemia (AML). It was a challenging time for her. With two young daughters — ages 7 1/2 years and 13 months — Momta said she had no choice but to fight for her life. Thankfully, she achieved complete remission. In 1997, Momta and her family moved to Clarkston, Georgia. Then, in late August 2021, she began feeling weak and fatigued and noticed she was bruising easily.Click Here to read full interview
